Morphine Injection Recall Issued Nationwide Over Risk of Mislabeled Opioid
A nationwide recall of one lot of Fresenius Kabi morphine injections has been announced after some syringes labeled as morphine may contain hydromorphone, a significantly more potent opioid.
A nationwide recall involving a commonly used injectable pain medication has raised concerns about the possibility of accidental opioid overdoses.
Fresenius Kabi has voluntarily recalled one lot of its Simplist Morphine Sulfate Injection USP, 2 mg/1 mL, after discovering that some prefilled syringes may have been incorrectly labeled. According to information released by the U.S. Food and Drug Administration (FDA), syringes carrying a morphine label could instead contain Dilaudid, or hydromorphone, at a concentration of 0.5 mg/0.5 mL.
The recall is particularly significant because hydromorphone is a powerful opioid and is generally considered substantially more potent than morphine on a milligram-for-milligram basis.
What caused the morphine injection recall?
The issue involves a labeling mix-up affecting a specific manufacturing lot of Fresenius Kabi's Simplist prefilled syringes.
The affected product is identified by lot number 6402820 and has an expiration date of December 2028. The affected syringes were distributed to wholesalers and distributors across the United States.
The concern is not that every syringe in the recalled lot necessarily contains the wrong medication. Rather, some syringes labeled as morphine may contain hydromorphone instead.
That creates a potentially serious medication safety problem because a healthcare professional administering the medication could believe they are giving morphine when the syringe actually contains hydromorphone.
Fresenius Kabi described the situation as having a reasonable probability of causing serious health consequences, including severe respiratory depression and death.
Why is hydromorphone a concern?
Morphine and hydromorphone are both opioid medications used to treat moderate to severe pain. However, they are not interchangeable on a simple one-to-one basis.
Hydromorphone is a semisynthetic opioid derived from morphine and is generally considered more potent. Its relative potency can vary depending on factors such as the route of administration and the individual patient.
This distinction is important in a hospital or clinical setting, where medication doses are carefully calculated according to a patient's medical condition, age, opioid tolerance and other medications.
If a patient receives an unintended opioid or an inappropriate dose, the medication can suppress the central nervous system and slow breathing. Severe opioid-related respiratory depression can become life-threatening without prompt medical attention.
Who may face the greatest risk?
According to information associated with the recall, certain patients could be particularly vulnerable to complications from an unintended hydromorphone exposure.
These include people who do not regularly take opioids, children, individuals with underlying respiratory conditions and patients who are taking other central nervous system depressants.
Central nervous system depressants can include certain medications that cause sedation. When combined with opioids, these substances can increase the risk of excessive sedation and breathing difficulties.
Healthcare professionals therefore need to carefully identify recalled products and follow established medication safety procedures.
What should healthcare facilities do?
Healthcare facilities that have the affected lot should immediately check their inventory and identify any syringes carrying the recalled lot number.
Fresenius Kabi has instructed facilities to stop distributing, dispensing or using affected products and arrange for their return.
Distributors have also been instructed to notify customers who received, or may have received, the recalled medication.
Because the product was distributed nationwide, facilities should not assume that the recall is limited to a particular state or region.
Medication recalls are designed to prevent potentially affected products from reaching additional patients. Prompt inventory checks can therefore be an important part of reducing the possibility of medication errors.
Have patients been harmed?
As of the recall information provided by Fresenius Kabi, no adverse health events had been reported in connection with the affected lot.
That does not mean the labeling issue is considered harmless. The company initiated the voluntary recall because of the potential consequences of administering an unintended opioid.
Patients who believe they may have received medication from an affected product should not attempt to diagnose or treat a possible opioid reaction on their own. They should contact their physician or healthcare provider for guidance, particularly if they develop concerning symptoms.
What symptoms can indicate an opioid emergency?
Opioid overdose can cause extreme sleepiness, confusion, slowed or difficult breathing, inability to wake up and other serious symptoms.
A person who becomes unusually difficult to awaken or develops severe breathing problems after receiving an opioid requires immediate medical attention.
Healthcare professionals are trained to recognize and manage opioid-related complications, including the use of appropriate emergency interventions when necessary.
The specific response depends on the circumstances and the patient's condition.
How can consumers get more information?
Fresenius Kabi has established a contact number for questions concerning the recall. Consumers and healthcare professionals can contact Fresenius Kabi USA Quality Assurance at 1-866-716-2459 during normal business hours.
The company has also advised patients to contact their physician or healthcare provider if they experience problems that may be associated with receiving the recalled medication.
Adverse reactions and quality concerns can also be reported through the FDA's MedWatch Adverse Event Reporting Program.
For the latest official information, healthcare professionals and consumers should rely on the FDA recall notice and communications from Fresenius Kabi rather than unofficial social media posts or third-party reports.
What this recall means for opioid safety
The recall highlights the importance of accurate medication labeling, especially when dealing with powerful drugs such as opioids.
Hospitals, pharmacies and other healthcare facilities use multiple safeguards to reduce medication errors. These may include checking product labels, verifying doses, confirming patient information and following procedures for recalled medications.
A labeling error involving two different opioid medications demonstrates why each step matters.
Although the recall involves a specific lot rather than all morphine injections, healthcare organizations should carefully review their supplies to determine whether the affected product is present.
Key details at a glance
- Manufacturer: Fresenius Kabi
- Product: Simplist Morphine Sulfate Injection USP, 2 mg/1 mL
- Issue: Some syringes labeled as morphine may contain hydromorphone
- Potential substitute medication: Dilaudid, or hydromorphone, 0.5 mg/0.5 mL
- Affected lot: 6402820
- Expiration date: December 2028
- Distribution: Nationwide in the United States
- Reported adverse events: None reported as of the recall announcement
- Primary concern: Potentially serious opioid-related respiratory depression and overdose
Source
U.S. Food and Drug Administration's recall and safety information concerning Fresenius Kabi's voluntary nationwide recall of the affected morphine injection lot.
Disclaimer
This article is for general informational and educational purposes only and is not medical advice. It should not be used to diagnose, treat or prevent any medical condition. Medication recalls and safety recommendations can change as investigations continue. Patients who believe they may have received an affected medication should contact a qualified healthcare professional for individualized advice. In an emergency or when serious symptoms are present, seek immediate medical care.